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CORRESPONDENCE
The case for stronger regulation 




Tuberculosis case management practices of private practitioners in low- and middle-income countries are commonly 
not in compliance with treatment guidelines, thus increasing the risk of drug resistance. National Tuberculosis control 
programs have long been encouraged to collaborate with private providers to improve compliance, but there is no 
example yet of a sustained, large scale collaborations with private practitioners in these settings. Regulations have 
long been realized as a potential response to poor quality care, however there has been a lack of interest from the 
international actors to invest in stronger regulation of private providers in these countries due to limited evidence 
and many implementation challenges. Regulatory strategies have now evolved beyond the costly conventional form 
of command and control. These new strategies need to be tested for addressing the challenge of poor quality care 
among private providers. Multilateral and bilateral funding agencies committed to tuberculosis control need to invest 
in facilitating strengthening government’s capacity to effectively regulate private providers.
© 2015 Mahendradhata. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
With an estimated 9.0 million incident cases in 2013, 
tuberculosis (TB) remains a major global health problem 
[1]. Most of the estimated number of cases occurred in 
low- and middle-income countries (LMICs) in Asia and 
the African Region. The six countries that stand out as 
having the largest number of incident cases in 2013 were 
India, China, Nigeria, Pakistan, Indonesia and South 
Africa [1]. Ironically, evidence is growing that many pri-
vate providers in these LMICs are putting populations at 
risk by delivering poor quality TB care [2–5].
Many symptomatic TB patients in LMICs, including 
the poor, seek care in the private sector. Studies suggest 
that 80 % of the first-contact health care and nearly 50 % 
of TB care in India occurs in the private sector [6]. A 
national survey on health-seeking behavior among pre-
sumptive TB cases in Indonesia showed that 54  % first 
sought treatment with a private practitioner (PP) [7]. 
Transportation and other non-medical expenses appear 
to raise barriers to seeking government health facilities. 
Private providers in LMICs have a higher probability 
of being the closest care provider as they are more fre-
quent in the community [8]. Another important reason 
which has also been shown to be an important reason for 
patients’ preferences for PPs is perceived high technical 
skills of the personnel [9].
Private providers however remain largely unregulated, 
with no effective policy or legislation to monitor them 
[10]. Consequently, TB diagnosis and treatment practices 
in the private sector is commonly not in line with current 
national and international guidelines [11, 12]. In Pune, 
India, despite a decade of training, high proportions of 
private providers resorted to TB serology for diagnosis 
[13]. A recent study in Andhra Pradesh, India reported 
that only one-third of PPs prescribed the correct tuber-
culosis TB treatment regimen while two-third prescribed 
a large variety of different prescriptions [14]. They also 
reported that many PPs prescribed second line anti TB 
drugs in contrary to international recommendation. The 
widespread use of second line anti-TB drugs in the pri-
vate sector in India, Pakistan and Indonesia has been well 
documented by a recent study [15]. Similar patterns of 
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insufficient knowledge and poor quality care among pri-
vate providers have also been reported for other diseases 
of public health importance, such as malaria [4, 16–18]. 
Poor TB case management practices are well known to 
increase the risk of drug resistance [19]. Thus, these dis-
turbing evidences of inappropriate TB case management 
among private providers in LMIC warrants considerable 
alarm for the global health community.
Collaboration with private providers have been advo-
cated as a key element of disease control strategy in 
LMICs [20–22]. Accordingly, the Public–Private Mix 
(PPM) approach have long been incorporated as a key 
component of the WHO’s Stop TB Strategy [23]. The 
Technical Review Panel of the Global Fund to fight 
AIDS, TB and Malaria also considers PPM as an impor-
tant attribute when assessing the technical quality of a 
proposal [24]. PPM in TB control thus has often been 
cited as examples of successful private provider engage-
ment. There is actually no example yet however of large-
scale, successful, sustained collaboration with private 
care providers for TB control [11, 25]. PPM have been 
demonstrated to be feasible in the cities of Pakistan, but 
with high cost [10]. Attempts to scale up PPM in 14 cit-
ies in India yielded varied results and revealed consid-
erable challenges as well as barriers [24]. Despite PPM 
efforts for many years, many PPs in India still could 
not prescribe correct TB treatment regimens [26]. It is 
seemingly unrealistic to expect National TB control Pro-
grammes (NTP) to be able to collaborate with thousands 
of PPs adequately and sustainably in high burden settings 
[26]. Furthermore, the reality is many private providers 
in these countries are not interested in partnering with 
NTPs [11, 24, 27].
Regulation is a key element, which has been practically 
neglected in previous efforts by disease control programs 
to address the challenges raised by private practitioners. 
Ironically, regulation actually has long been recognized 
as a potential response to address the many problems 
which arise in the private delivery of health services [28]. 
It is seen as having a crucial balancing role in the con-
text of uncontrolled growth of the private sector. Studies 
in India revealed that factors that contribute to the poor 
quality of services offered by the private sector are a lack 
of monitoring by authorities, outdated and inadequate 
legislation, and the inability or failure of the government 
to enforce existing regulations [29]. Poor regulation has 
also been identified as one of the key barriers for suc-
cessful engagement of private providers in TB control 
[11, 30]. The neglect of regulation by NTPs in previous 
strategies to deal with private providers however seem-
ingly has been based on the argument that regulations 
are easier to enact than enforce in the current context 
of weak health systems in LMICs and that regulation 
cannot be a panacea to guarantee adherence to rules by 
all care providers [31, 32]. There are elements of truth in 
such argument.
The challenges of regulating PPs’ case 
management practices in LMICs
NTP have little power over PPs in LMICs as quality 
of healthcare provision in these settings is essentially 
addressed through the self-regulating function of medi-
cal professionals [33]. Some middle-income countries 
are now also starting to use accreditation as a means to 
improve quality and standards of facilities. Despite the 
existence of these basic regulatory legislation in most 
LMICs, the degree to which regulations are enforced 
is low [28]. Regulation enforcement in Zimbabwe has 
been reported to be mired by weaknesses of the main 
regulatory body (i.e. the Health Professions Council), 
inadequate design of current regulation and insufficient 
resources [34]. India’s formal approach of enforcing reg-
ulations through administrative and bureaucratic con-
trols does not appear to be working well, despite having 
established a comprehensive formal legal system that 
provides a minimum of protection to the public [35]. The 
respective medical councils in states in India have been 
reported to not be enforcing the laws relating to the reg-
istration and licensing of individual practitioners [29]. 
The gap in effective regulation in India has also been 
exacerbated by the interests of the health professions, 
which have not focused on the key regulatory concerns 
[28]. In China, key challenges of health care regulation 
include weaknesses in the regulatory capacity of local 
governments, their accountability and the limited voice 
for consumers through the media or civil society [36].
Each country evidently poses specific challenges 
for effective health care regulation. Some general pat-
terns however can be observed. Institutional capacity 
for enforcing regulation for instance is generally weaker 
in low income countries (LICs) than in middle income 
countries (MICs) [37]. MICs may have more resources 
to channel into regulation. In Thailand, roles and respon-
sibilities of regulators were found to be comprehensive 
and administrative structures, rules, incentives as well 
as standards were in place [37]. This suggests that Thai-
land has reached a stage of institutional capacity which 
has not been achieved in LICs, mostly due to the lack of 
institutional development and the limited availability of 
resources.
The findings above however do not justify throwing out 
the baby with the bath water. First, it is not realistic to 
expect to have effective health care regulation systems in 
place within a short period. Even in affluent settings such 
as US, it took generations for regulatory bodies such as 
the Food and Drug Administration to achieve its status 
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as an internationally respected, science-driven regulator, 
and still they are not without problems [38]. Despite the 
complexity and the problems of the health care regulation 
system in the US, it remains to be considered essential for 
the health care system to function well [39]. Second, it 
is impossible to implement well any regulatory strategy 
with inadequate resources. Regulation is clearly not cost-
less, requiring skilled personnel and unit with adequate 
resources for data collection, inspection and monitoring 
[37]. The introduction of accreditation as a quality con-
trol measure in India for instance received widespread 
support from both public sector regulators and private 
hospitals, but implementation was eventually hampered 
by lack of resources to finance the accreditation system 
[37]. Third, most of the challenges revolved around tra-
ditional methods of implementing regulations include 
mechanisms for monitoring, inducing compliance, 
and penalizing non-compliance [40]. These traditional 
forms have a long-established history in the industrial-
ized countries and are highly resource intensive. Conse-
quently they have been difficult for LMICs to implement. 
Less cumbersome and expensive regulatory approaches 
have been developed in recent years [40]. Hence, instead 
of dismissing regulation outright, the way forward is to 
consider these non-conventional approaches and strate-
gies that may be more appropriate and more effective for 
LMICs.
Potential nonconventional regulatory approaches 
and strategies
Non-conventional approaches may provide alterna-
tive means for effectively addressing the issue of poor 
quality care among PPs in LMICs. Mok and colleagues 
highlighted two strategies which are considered to be 
low-cost, yet potentially effective: written notices and 
public disclosure [40]. In the case of PPs, written notices 
of non-compliance to standards offer a potentially cost-
effective way to enforce regulations. Warning letters do 
not require any official collection of data by the regula-
tory body as they do not carry any force of law. The PP 
can discuss with the regulatory body to resolve the issue 
if he feels that there are justifications for non-compliance. 
The warning letter simply serves as notice that the regu-
latory body believes there is non-compliance and that 
tougher actions could follow if the PP does not change 
its behavior. Such written notices have been reported 
to be a particularly effective way to induce compliance 
with regulations and standards, especially when used 
in conjunction with public disclosure [40]. Public dis-
closure itself has been reported to be an efficient way of 
enforcing compliance with regulations. Regulatory bod-
ies for instance can release information on PP’s poor case 
management practice to the public. The threat of public 
pressure has been reported to be effective in achieving 
regulatory goals without coercion [40].
Healy and Braithwaite proposed a responsive regula-
tion approach, in which regulators employ a series of 
mechanisms that are responsive to the context, con-
duct and culture of those being regulated [41]. The core 
of this approach is a pyramid of regulatory mechanisms 
that range upwards, encompassing voluntarism, market 
mechanism, self-regulation, metaregulation, command 
and control [41]. Thus, in the case of substandard case 
management among PPs, regulators could use the pyra-
mid to think responsively in choosing among a cascade 
of regulatory options (Fig.  1). Mok and colleagues also 
proposed a similar concept, refering it to as a cascading 
hierarchy of sanctions [40].
Black suggested the concept of de-centered regulation, 
which expands regulatory activities concept to actors 
beyond the state and measures beyond the traditional 
command and control [42]. The de-centered approach 
thus basically allows non-state actors to be involved in 
producing, monitoring and enforcing regulations that are 
aimed to influence behavior and regulatory outcomes. 
In the case of substandard case management among 
PPs, health agencies could thus collaborate with the key 
stakeholders (e.g. registration body, licensing body, medi-
cal association, patient group, civil societies and repre-
sentatives of PPs) to set case management standards and 
establish information exchange mechanisms [37]. The 
emphasis on co-regulation could facilitate negotiated 
agreement on roles and responsibilities between the PPs 
and other actors, leading to a new role and capacity for 
health authorities, requiring engagement and collabora-
tive forums [37].
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Fig. 1 Cascade of options for regulating private practitioners’ compli-
ance to tuberculosis (TB) diagnosis and treatment standards (adapted 
from Healey and Braithwaite [41] and Mok et al. [40])
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Discussions
Expecting that NTPs could collaborate effectively with 
thousands of private providers in the context of limited 
resources and competing resources has proven to be 
unrealistic. The longstanding dismissal of the essential 
role of regulation has thus contributed to persistent inap-
propriate TB case management practices among PPs, 
with dire consequences for NTPs and patients. Regula-
tion clearly has its challenges and cannot be expected to 
solve all the problems associated with PPs (as there is no 
silver bullet to resolve any complex challenge). Nonethe-
less, governments must not shirk from the challenges of 
regulatory responsibilities as it is their duty to act in the 
best interests of the whole population [43]. Poor regu-
lation of health care is a symptom of poor governance 
[35]. The lack of regulation thus actually sends the wrong 
messages about acceptable case management practices 
among PPs.
The non-conventional regulatory strategies and 
approaches described here are not intended to provide a 
one-size-fits-all solution to poor case management prac-
tices among PPs in LMICs. Regulatory systems in these 
countries operate in the context of different political con-
ditions and face different sets of challenges. Hence, the 
presented regulation strategies and approaches will have 
to be adapted to suit the particular contexts, needs and 
availability of resources. It is also recognized that regu-
latory approaches are more likely to succeed if packaged 
in bundles [44]. Notably, there is no evidence yet that the 
non-conventional strategies and approaches described 
above will work in addressing the problem of poor case 
management practices among PPs in LMICs. That 
remains to be tested. The limited evidence of effective-
ness actually applies to the general scope of health care 
regulatory approaches in LMICs [37]. This is mainly due 
to the lack of opportunities to test regulatory interven-
tions, which in turn block much needed progress. Fun-
damentally, regulation should not be static but should 
rather be continuously adapted [44]. Thus regulations 
should always be introduced along with rigorous analytic 
approaches [44].
Efforts to assist LMICs in the development of regula-
tory frameworks and techniques unfortunately are still 
lagging [37]. There is also a lack of efforts in institu-
tional capacity and seeking different ways of achieving 
regulatory objectives. Regulation clearly needs adequate 
resources in order to be successfully implemented. 
Investment requirements to strengthen local capacity 
for health care regulation could be relatively high, but 
it will help countries secure their ability in the long run 
to address the challenges raised by the rapid growth of 
private health providers in resource constrained settings 
[45, 46], independent of donor support. Thus it offers a 
potentially sustainable solution to a longstanding prob-
lem. Clearly, effective TB control in LMICs requires 
effective regulation of TB case management among 
PPs. Multilateral funding agencies (e.g. the Global fund 
to Fight AIDS, TB and Malaria) and bilateral funding 
agencies (e.g. USAID) committed to TB control should 
provide investment for piloting innovative regulatory 
strategies and strengthening goverment’s capacity to 
effectively regulate private care providers in LMICs.
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